Evidence map›Paper›PMID 36915205›Full record

Trial reportBMC research notes2023

Can a 3 months treatment with oral Desogestrel prior to insertion of the etonogestrel-releasing contraceptive implant improve continuation rate at 1 year? A randomized trial.

Valeria Lombardi Fäh, Rosa Catarino, Sarah Castillo, Maria Badda, Sibel Gezer-Dickschat, Friederike Thieringer, Sibil Tschudin, Manuela Viviano, Michal Yaron

Registry-linked trialOpen access · goldFull text readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC research notes, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05174195 (Can a Three Months Treatment With Oral Desogestrel Prior to Insertion of the Etonogestrel Subdermal Implant Improve Continuation Rate at One Year?), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05174195 naterminatednot on this map

Can a Three Months Treatment With Oral Desogestrel Prior to Insertion of the Etonogestrel Subdermal Implant Improve Continuation Rate at One Year?

TypeinterventionalSponsorUniversity Hospital, GenevaRan2016 to 2019Enrolled67ConditionsContraception, Progestogen Adverse ReactionArmsDesogestrel 0.075 milligram, Implanon NXT® subdermal implant
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Valeria Lombardi FähService of Gynecology, Department of Woman, Child and Adolescent, Geneva University Hospitals, Boulevard de La Cluse 30, 1205, Geneva, Switzerland. valeria.lombardifah@hcuge.ch.ORCID http://orcid.org/0000-0002-1621-6653
Rosa CatarinoService of Gynecology, Department of Woman, Child and Adolescent, Geneva University Hospitals, Boulevard de La Cluse 30, 1205, Geneva, Switzerland.
Sarah CastilloService of Gynecology and Obstetrics, Hospital Neuchâtel-Pourtalès, Rue de La Maladière 45, 2000, Neuchâtel, Switzerland.
Maria BaddaService of Gynecology and Obstetrics, GHOL - Hospital Nyon, Chemin Monastier 10, 1260, Nyon, Switzerland.
Sibel Gezer-DickschatService of Gynecology and Obstetrics, University Hospital Basel, Universitätsspital CH, Petersgraben 4, 4031, Basel, Switzerland.
Friederike ThieringerService of Gynecology and Obstetrics, University Hospital Basel, Universitätsspital CH, Petersgraben 4, 4031, Basel, Switzerland.
Sibil TschudinService of Gynecology and Obstetrics, University Hospital Basel, Universitätsspital CH, Petersgraben 4, 4031, Basel, Switzerland.
Manuela VivianoService of Gynecology, Department of Woman, Child and Adolescent, Geneva University Hospitals, Boulevard de La Cluse 30, 1205, Geneva, Switzerland.
Michal YaronService of Gynecology, Department of Woman, Child and Adolescent, Geneva University Hospitals, Boulevard de La Cluse 30, 1205, Geneva, Switzerland.
University Hospital of Geneva · CHUniversity Hospital of Basel · CHHospital Neuchâtel · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate if daily oral 75 µg of Desogestrel (DSG) for 3 months prior to the insertion of etonogestrel-releasing contraceptive implant (ENG-IMPLANT) might help reduce its premature discontinuation.

resultsA total of 66 women were randomized in the ENG-IMPLANT group (26) and in the DSG + ENG-IMPLANT group (40), respectively, in the Geneva University Hospitals and Basel University Hospital, from August 15th, 2016 through September 30th, 2019. In the DSG + ENG-IMPLANT group, patients were given a 3 months' supply of 75 µg of DSG before the insertion of the ENG-IMPLANT. All women were seen after 3 months for bleeding and satisfaction evaluation, and at 12 months post ENG-IMPLANT insertion. Higher levels of satisfaction at 12-months were found in the ENG-IMPLANT group compared to the DSG + ENG-IMPLANT group (8.5 ± 1.7 vs. 6.6 ± 2.9, p = 0.012). There were no statistically significant differences regarding tolerance (7.8 ± 2.5 vs 6.8 ± 2.6, p = 0.191) and contraceptive continuation (80% vs 72.4%, p = 0.544) between groups.

conclusionDSG prior to insertion of the ENG-IMPLANT did not improve its continuation rate neither its satisfaction at 1 year. Trial registration NCT05174195. Retrospectively registered, the 30th December 2021.

Indexed as

Contraceptive Agents, FemaleDesogestrelFemaleHumansLevonorgestrelTime FactorsContraceptive Agents, FemaleDesogestreletonogestrelLevonorgestrelDesogestrel pillDiscontinuationEtonogestrel-releasing contraceptive implantLong-acting reversible contraceptives (LARC)Tolerance

Identifiers

PMID36915205
PMCPMC10010063
OpenAlexW4324129455

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read33
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.